![]() ![]() ![]() Elsewhere in the market, the S&P 500 Index has stumbled -1.45% in last trading session, with the Dow Jones Industrial also saw a negative session on the day with -1.07%.Īn analysis of the NeoGenomics Inc. Also, Laboratory Corporation of America Holdings (LH) showed down trend of -0.70% while its price kept floating at -16.21% over the past year. (RDNT) whose stock price was down -1.31% in the last trading session, and has flourished 9.81% over the past year. stock has performed in comparison to its peers in the industry, here’s what we find: NEO’s stock is -7.19% on the day and -11.60% in the past 12 months, while Quest Diagnostics Incorporated (DGX) traded -0.43% in the last session and was positioned -0.94% down on its price 12 months ago. Turning out attention to how the NeoGenomics Inc. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy. On the technical perspective front, indicators give NEO a short term outlook of 100% Buy on average. Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. Per this projection, the revenue is forecast to grow 3.50% above that which the company brought in 2022. Staying with the analyst view, there is a consensus estimate of $501.07 million for the company’s annual revenue in 2022. The average estimate suggests sales growth for the quarter will likely rise by 3.40% when compared to those recorded in the same quarter in the last financial year. On average, analysts have forecast the company’s revenue for the quarter will hit $129.97 million, with the likely lows of $126.2 million and highs of $132.3 million. In this case, analysts estimate an annual EPS growth of -151.90% for the year and 22.10% for the next year. Analysts tracking NEO have forecast the quarterly EPS to shrink by -0.16 per share this quarter, while the same analysts predict the annual EPS to hit -$0.68 for the year 2023 and up to -$0. NeoGenomics Inc., which has a market valuation of $2.30 billion, is expected to release its quarterly earnings report – May 01, 2023. Don't wait - get our free report today!ĭownload Your FREE Green Energy Report & Unlock Your Investment Potential Today! ![]() Get the best of both worlds with multiple salt dome opportunities in the green hydrogen space and precious metals development. Invest in the Green-Energy Revolution now with our free report! Discover small-cap mineral exploration companies set to be the next suppliers of green energy. Act Now and Secure Your Future in Green Energy! ![]()
0 Comments
Leave a Reply. |